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Articles
Endocrine and haemodynamic changes in resistant 
hypertension, and blood pressure responses to 
spironolactone or amiloride: the PATHWAY-2 mechanisms 
substudies
Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, 
Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown, for The British Hypertension Society programme of 
Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group*
Summary
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially 
more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this 
superiority and the pathogenesis of resistant hypertension.
Methods PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites 
in 314 patients with resistant hypertension. Patients were given 12 weeks of once daily treatment with each of placebo, 
spironolactone 25–50 mg, bisoprolol 5–10 mg, and doxazosin 4–8 mg and the change in home systolic blood pressure 
was assessed as the primary outcome. In our three substudies, we assessed plasma aldosterone, renin, and 
aldosterone-to-renin ratio (ARR) as predictors of home systolic blood pressure, and estimated prevalence of primary 
aldosteronism (substudy 1); assessed the effects of each drug in terms of thoracic fluid index, cardiac index, stroke 
index, and systemic vascular resistance at seven sites with haemodynamic monitoring facilities (substudy 2); and 
assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week 
open-label runout phase (substudy 3). The PATHWAY-2 trial is registered with EudraCT, number 2008–007149–30, 
and ClinicalTrials.gov, number NCT02369081.
Findings Of the 314 patients in PATHWAY-2, 269 participated in one or more of the three substudies: 126 in substudy 1, 
226 in substudy 2, and 146 in substudy 3. Home systolic blood pressure reduction by spironolactone was predicted by 
ARR (r²=0·13, p<0·0001) and plasma renin (r²=0·11, p=0·00024). 42 patients had low renin concentrations (predefined 
as the lowest tertile of plasma renin), of which 31 had a plasma aldosterone concentration greater than the mean value 
for all 126 patients (250 pmol/L). Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately 
high aldosterone concentrations. Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; 
p<0·0001) with spironolactone, but not other treatments. Amiloride (10 mg once daily) reduced clinic systolic blood 
pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with 
spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not 
systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased 
from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).
Interpretation Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to 
inappropriate aldosterone secretion. Mineralocorticoid receptor blockade by spironolactone overcomes the salt 
retention and resistance of hypertension to treatment. Amiloride seems to be as effective an antihypertensive as 
spironolactone, offering a substitute treatment for resistant hypertension.
Funding British Heart Foundation and UK National Institute for Health Research.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Resistant hypertension is defined as a blood pressure that 
is uncontrolled despite treatment with at least three blood 
pressure-lowering drugs, including a diuretic, usually 
also including an angiotensin-converting enzyme (ACE) 
inhibitor or angiotensin receptor blocker (ARB) and a 
calcium channel blocker (CCB), and after exclusion of 
treatable secondary causes of hypertension.1 Resistant 
hypertension affects up to 10% of patients treated for 
hypertension and is associated with a high risk of 
cardiovascular morbidity and mortality.2 In the random-
ised, placebo-controlled crossover trial PATHWAY-2,3 
we tested the recommendation4 to treat resistant 
hyper tension by addition of a drug that blocks either 
the mineral ocorticoid or adrenergic receptors. In 
PATHWAY-2, the mineral ocorticoid receptor antagonist 
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spironolactone (25–50 mg per day) was more effective at 
lowering blood pressure than bisoprolol (5–20 mg daily), 
doxazosin (4–8 mg daily), or placebo.3 This finding is 
supported by evidence from observational studies.5
Understanding the mechanism of the blood pressure-
lowering superiority of spironolactone in resistant 
hypertension would help to delineate the patho-
physiological basis of resistant hypertension and provide a 
rationale for developing alternative treatment strategies for 
patients in whom spironolactone is poorly tolerated. The 
hypothesis underpinning PATHWAY-2 was that resistant 
hypertension is predominantly a sodium-retaining 
state (despite background treatment with thiazide-type 
diuretics) and that further diuretic (more correctly, 
natriuretic) treatment would be the most effective means 
of lowering blood pressure.3 PATHWAY-2 incorporated a 
series of prespecified hormonal and haemodynamic 
measurements designed to facilitate investigation of the 
pathophysiology of resistant hyper tension and its drug 
treatment.6 We now report the results of these analyses, 
which address three clinically important questions.
First, what is the relation between baseline plasma 
renin, aldosterone, and the aldosterone-to-renin ratio 
(ARR) and the blood pressure-lowering response to 
spironolactone, bisoprolol, doxazosin, and placebo? Con-
sistent with our hypothesis that resistant hypertension is 
See Online for appendix
Research in context
Evidence before this study
We previously reported the results of the PATHWAY-2 
randomised controlled trial, which showed that low-dose 
spironolactone (25–50 mg daily), when added to standard blood 
pressure-lowering drugs, was substantially more effective at 
lowering blood pressure in patients with resistant hypertension 
than placebo or alternative blood pressure-lowering drugs 
(bisoprolol or doxazosin). On Sept 17, 2017, we searched 
MEDLINE, Embase, and the Cochrane Central Register of 
Controlled Trials using the search terms “resistant hypertension”, 
“pathophysiology”, “mechanisms”, “amiloride”, 
“hemodynamics”, and “aldosterone” for reports in English 
published up to July 31, 2017. Our search strategy included 
reports of randomised controlled trials as well as open and 
observational studies of drug treatment of resistant 
hypertension that included any data analysing mechanisms and 
pathophysiology of resistant hypertension or the use of 
amiloride. The available evidence was scarce. Findings from 
two observational studies had suggested that plasma renin 
concentrations were often more suppressed than anticipated in 
patients with resistant hypertension, consistent with this being 
a sodium-retaining and volume-expanded state. In another 
study, non-invasive haemodynamic measurements via 
impedance cardiography were used to establish whether 
treatment adjusted on the basis of haemodynamic 
characteristics would be more effective than empirical treatment 
at lowering blood pressure in resistant hypertension, but the 
findings were inconclusive. In a prospective study of 
88 consecutive patients referred to a university clinic for 
resistant hypertension, researchers reported that 18 (20%) had 
increased urinary aldosterone and suppressed plasma renin 
concentrations, despite salt intake in excess of 200 mmol/24 h. 
Background treatment, including β-blockade, was not 
discontinued. Authors of other observational studies and 
commentaries have speculated that many cases of resistant 
hypertension might result from undetected 
aldosterone-producing adenomas. Results of many studies have 
shown the efficacy of low-dose (2·5–5·0 mg) amiloride added to 
thiazide, including reduction of morbidity and mortality. We 
have previously reported the efficacy of high-dose (10–40 mg) 
amiloride in treated hypertension, but amiloride has not 
previously been compared with spironolactone or other drugs in 
patients with resistant hypertension.
Added value of this study
In the PATHWAY-2 trial, spironolactone reduced blood 
pressure substantially more than conventional 
antihypertensive drugs in patients with resistant 
hypertension. In order for the results of PATHWAY-2 to change 
practice, it was important to show a mechanistic basis 
underpinning the superiority of spironolactone. The results of 
the PATHWAY-2 mechanisms substudies show that the 
efficacy of spironolactone as an antihypertensive drug could 
be anticipated from our findings that resistant hypertension is 
a salt-retaining condition, associated with high 
aldosterone-to-renin ratios, and that spironolactone was 
substantially superior to the other standard antihypertensive 
drugs in reducing indices of salt and water retention—ie, it was 
reducing blood pressure primarily via diuretic actions. 
Physicians who are hesitant to prescribe spironolactone for 
hypertension, either because it is not a universally licensed 
indication, or because of antiandrogen-related intolerance, 
will be reassured by our additional finding that amiloride 
10–20 mg achieved similar reductions in blood pressure as 
spironolactone, with similar, slight changes in electrolytes.
Implications of all the available evidence
We propose that spironolactone, or amiloride if spironolactone 
is not tolerated, should be first-line treatment for resistant 
hypertension, in addition to background treatment with an 
angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker, a calcium channel blocker, and a diuretic, in 
patients with an eGFR greater than 45 mL/min/1·73m² and 
serum potassium within the normal range. Among this cohort 
are likely to be some —perhaps many—patients whose 
hypertension is caused by primary aldosteronism. We 
encourage a reconsideration of which diagnostic thresholds for 
primary aldosteronism are appropriate in patients with 
resistant hypertension, to facilitate recognition of a potentially 
curable aldosterone-producing adenomas in patients with 
resistant hypertension.
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predominantly a sodium-retaining state, we expected 
plasma renin to be relatively suppressed despite 
back ground treatment with an ACE inhibitor or an ARB, 
a CCB, and a diuretic—ie, the so-called A+C+D treatment 
strategy.3,4 A finding of a suppressed renin concentration, 
despite treatments that usually increase plasma renin, 
would be consistent with resistant hypertension being a 
sodium-retaining state. We also hypothesised that the 
blood pressure-lowering response to spironolactone, but 
not to other drugs, would be greatest in participants with 
the lowest plasma renin concentrations and highest 
ARRs, consistent with sodium retention being largely a 
consequence of auto nomous aldosterone production. The 
proportion of patients exceeding validated thresholds for 
the diagnosis of primary aldosteronism was also assessed.
Second, we aimed to assess the haemodynamic 
responses to the various drug treatments and placebo 
and their effect on cardiac output, systemic vascular 
resistance, and thoracic fluid content, testing the 
hypothesis that the superior action of spironolactone in 
lowering blood pressure in resistant hypertension would 
be consistent with those of a diuretic.
Third, we hypothesised that if the superiority of 
spironolactone in resistant hypertension was due to its 
natriuretic actions, then amiloride would similarly 
decrease blood pressure. Like spironolactone, amiloride 
is a distal tubular diuretic that inhibits the aldosterone-
sensitive epithelial sodium channel. Notably, a low-dose 
thiazide and amiloride combination achieved a greater 
reduction in blood pressure from baseline than high-dose 
thiazide alone in patients with hypertension in the 
PATHWAY-3 trial.7
Methods
Study design and participants
PATHWAY-2 was a 12-month, double-blind, placebo-
controlled, randomised, crossover trial done at 12 secondary 
care sites and two primary care sites in the UK, in patients 
aged 18–79 years with systolic blood pressure of at least 
140 mm Hg and home systolic average blood pressure of at 
least 130 mm Hg despite treatment with maximum 
tolerated doses of three blood pressure-lowering drugs 
(ie, A+C+D). Secondary causes of hypertension had been 
excluded and specific procedures were done to confirm 
resistant hypertension and patient adherence to their 
baseline medications.6 In the final year of PATHWAY-2, a 
new mass spectrometric assay permitted a spot urine test 
at baseline and the end of each double-blind phase to be 
checked for background and study drugs.8
The haemodynamics and amiloride runout substudies 
were incorporated within the original protocol of 
PATHWAY-2, and the aldosterone substudy was added 
later. By design, each was done in a subset of patients, 
restricted by either recruitment date (aldosterone 
measurements [substudy 1]), setting (haemodynamic 
measurements [substudy 2]), or preference of the patient 
or doctor (amiloride runout [substudy 3]).3,6 The overall 
design of PATHWAY-2 and its incorporated substudies is 
shown in figure 1. Patients from the intention-to-treat 
population in the main study were included in analysis 
of substudy 1 when measurements of aldosterone and 
renin were available; substudy 2 when measurements 
of haemodynamic parameters were available; and 
substudy 3 when clinic blood pressure readings after 
receiving at least one dose of amiloride were available.
In 2012, roughly halfway through recruitment for 
PATHWAY-2, additional funding permitted the addition 
of plasma aldosterone, and thus ARR, to the baseline 
measurements. The objective of substudy 1 was to 
compare the ability of plasma aldosterone, renin, and 
ARR to predict the blood pressure response to each drug 
and to explore the role of aldosterone in patients with 
resistant hypertension. Thus, patients recruited after 
2012 with available baseline aldosterone measurements 
were included in substudy 1.
Patients were eligible for substudy 2 dependent on which 
location they were recruited from; seven of the 12 secondary 
care sites had the necessary specialist equipment. 
Substudy 2 assessed the effects of spironolactone, 
bisoprolol, and doxazosin treatments on thoracic fluid, 
cardiac index, and systemic vascular resistance and 
whether patients’ most effective drug was predicted by 
increased baseline measurements of the parameter most 
likely to be reduced by that drug.
After the double-blind rotation, patients were offered the 
option of returning to primary care or continuing into an 
open-label runout phase (substudy 3). This opportunity for 
a non-randomised study of an alternative to spironolactone 
arose from the need for a period between each patient’s 
final visit and completion of their electronic record, after 
which their best treatment could be unmasked. In this 
open-label phase, we assessed whether amiloride would 
have similar superiority to the other study drugs as was 
hypothesised for spironolactone, and, if so, whether a 
correlation between responses would support switching 
from spironolactone to amiloride in patients who became 
intolerant of spironolactone.
All study participants provided written informed 
consent as part of consent for the main trial and the 
protocol for these studies was approved by the Cambridge 
South Research Ethics Committee.
Procedures
In the main PATHWAY-2 trial, after a 4-week single-
blind placebo run-in, patients rotated through four 
cycles of once-daily oral treatment with spironolactone 
25–50 mg, doxazosin 4–8 mg, bisoprolol 5–10 mg, and 
placebo, each for 12 weeks with forced titration to the 
higher dose after 6 weeks. The order in which drugs 
were administered to each patient was randomly 
assigned via a central computer system. Patients and 
investigators were masked to drug treatment groups. 
Blood was collected at the end of the placebo run-in, and 
batched results did not inform eligibility of individual 
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patients for either the main trial or its substudies. 
Plasma renin was measured in a central laboratory as 
direct renin mass using the LIAISON automated 
chemiluminescent immunoassay (DiaSorin, Saluggia, 
Italy).9 Plasma aldosterone was also measured using the 
LIAISON automated chemiluminescent im munoassay10 
or by mass spectrometry.
For substudy 2, non-invasive haemodynamic assess-
ments of fluid balance, cardiac performance, and 
vascular resistance were done with the patient supine, 
at baseline and at the end of each treatment cycle, 
using thoracic electrical bioimpedance cardiography 
(CardioDynamics BioZ Impedance Cardiography 
Hemodynamic Monitor, CardioDynamics, San Diego, 
CA, USA).10 Four pairs of electrocardiogram electrodes 
were applied to the base of the neck and the lower thorax 
at the diaphragm level, and a high frequency, low 
magnitude current was applied. The difference between 
input and sensed voltage is established by the impedance 
of the thorax, which is inversely proportional to thoracic 
fluid volume. Stroke volume is calculated from the 
change of impedance (thoracic fluid content) over the 
cardiac cycle time. Because cardiac output and total 
body fluid volume is related to body mass, all blood flow 
parameters were indexed to body surface area in m². 
Stroke index was calculated as stroke volume divided by 
body surface area (mL per heart beat per m²). Cardiac 
index (cardiac output) was calculated as stroke index 
multiplied by heart rate (L/min/m²). Systemic vascular 
resistance index was then derived from the 
measurements of cardiac index and blood pressure 
(dyn ×   sec/cm⁵/m²). Thoracic fluid content index, an 
index of body fluid volume, is expressed as 1/kΩ/m². 
Previous studies have shown these primary variables to 
be highly reproducible on repeated measures in the 
same patient, separated by days or weeks.10,11
In substudy 3, participating patients received amiloride 
10 mg once daily for 6 weeks, followed by the option to 
up-titrate to 20 mg daily for a further 6 weeks if blood 
pressure remained uncontrolled (figure 1). Seated clinic 
blood pressure was measured after 6 and 12 weeks of 
amiloride treatment.
In the main PATHWAY-2 study, blood pressure was 
measured both as a home blood pressure average and 
seated clinic blood pressure. For substudy 1 examining the 
relations between hormones and the blood pressure 
response to treatment, home systolic blood pressure 
measurements were used. Home blood pressure was a 
single mean of 24 seated home blood pressure readings 
recorded in the morning and evening for 4 consecutive 
days, with triplicate readings at each measurement 
session. Home blood pressure was recorded over the 
4 days before the baseline visit at the end of placebo run-in, 
and before the 6-week and 12-week visits of each double-
blind treatment cycle. If incomplete, a minimum of 
six of the 24 possible blood pressure recordings over 4 days 
was required, or patients were excluded from the analysis. 
Home blood pressure was not recorded during the 
open-label amiloride runout phase. Thus in substudy 3, 
the clinic blood pressure-lowering effect of amiloride was 
compared with clinic blood pressure reduction on other 
active treatments or placebo. Clinic blood pressure was 
the average of the last two of the triplicate readings 
recorded at the 6-weekly study visits during both the 
double-blind treatment cycles and the open-label 
amiloride runout. Visits could be morning or afternoon, 
Placebo once per day for 
12 weeks
Amiloride open-label
12-week run-out
(10–20 mg once per day)
Screening for resistant hypertension
Treatment A+C+D
Directly observed therapy to exclude 
non-compliance
Home blood pressure measurement to 
exclude white coat hypertension
Secondary hypertension excluded
Doxazosin 4–8 mg once 
per day for 12 weeks
Home systolic blood 
pressure measured at
6 and 12 weeks
Spironolactone 25–50 mg 
once per day for 12 weeks
Haemodynamic assessments at
baseline and at 6 weeks and
12 weeks of each treatment cycle
Bisoprolol 5–10 mg once 
per day for 12 weeks
Plasma renin, aldosterone, 
and aldosterone-to-renin 
ratio
Group assignment
Baseline
4-week single-blind
placebo run-in
(treated with A+C+D)
Figure 1: PATHWAY 2 study design
Stages in the crossover trial at which measurements for the three mechanistic substudies were taken. Green shows substudy 1, blue shows substudy 2, and pink 
shows substudy 3. During the 12-week drug cycles, the lower dose was given for the first 6 weeks, then the higher dose was given for the second 6 weeks. No washout 
period was used between cycles. The figure shows one of the 24 possible passages through the drug cycles, the order of which was randomly assigned within blocks of 
24 patients. A+C+D=an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a calcium channel blocker, and a diuretic.
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but were at a consistent time of day for each patient. The 
home and clinic blood pressures were measured by a 
WatchBP Home monitor (Microlife, Clearwater, FL, USA), 
allocated to the patient for the year of double-blind 
treatment.
Outcomes
The prespecified objectives and outcome measures for 
these mechanistic substudies of the PATHWAY-2 trial 
were to define the relations between baseline plasma 
renin, aldosterone, and ARR (on background treatment 
with A+C+D) and the blood pressure response to 
spironolactone, doxazosin, bisoprolol, and placebo; to 
analyse the haemodynamic response to the blood 
pressure-lowering treatments in resistant hypertension 
to establish their most likely mechanism of action; and to 
use the open-label runout phase of the study to establish 
whether amiloride would achieve blood pressure 
reductions similar to spironolactone in patients with 
resistant hypertension. Exploratory analyses of the 
prevalence of primary aldosteronism were also done. 
Only serious adverse events were recorded during the 
open-label amiloride runout.
In the aldosterone substudy (substudy 1) of patients who 
had a baseline measurement of ARR, the main outcomes 
were the baseline measurement of ARR, and the 
regression upon this of the change from baseline in home 
systolic blood pressure averaged (mean) across the 6-week 
and 12-week visits of each double-blind treatment. In the 
haemodynamic substudy (substudy 2) of patients at the 
seven sites that had a CardioDynamics BioZ Impedance 
Cardiography Hemodynamic Monitor (SonoSite, 
San Diego, CA USA), the main outcomes were the 
changes in thoracic fluid index, cardiac index, stroke 
index, and systemic vascular resistance between baseline 
and the end of each double-blind treatment. In the 
amiloride substudy (substudy 3) of patients who continued 
after the double-blind treatment cycles into an optional 
open-label runout on amiloride, the main outcome was 
change in clinic systolic blood pressure between baseline 
and end of 6 weeks (low-dose) or 12 weeks (high-dose) of 
amiloride treatment. In all substudies, treatment refers to 
the study drug administered in addition to the background 
treatment with A+C+D (an ACE inhibitor or an ARB, a 
CCB, and a diuretic).
Statistical analysis
This PATHWAY-2 mechanisms study is a series 
of prespecified substudies embedded within the 
PATHWAY-2 trial.6 The sample size and statistical power 
calculations were done for the primary outcome of the 
PATHWAY-2 trial and do not apply to these substudies.
In substudy 1, we used regression analyses to explore 
the relation between each of baseline plasma renin, 
aldosterone, and the ARR and blood pressure responses 
to the active treatments and placebo. Exploratory analyses 
were post hoc, but when appropriate followed the 
prespecified PATHWAY definition of high and low renin 
concentrations being those within the upper and lower 
tertiles of the plasma renin distribution. The prevalence 
of primary aldosteronism was estimated using the 
threshold of 60·94 pmol/mU for ARR in the post-
captopril suppression test, and a threshold of 5·3 (mmol 
L–¹)–¹ for the SUSPPUP ratio ([serum sodium/urinary 
sodium])/([serum potassium²/urinary potassium]).12,13 In 
substudy 2, for analysis of haemodynamic responses to 
drug treatment, and to assess them as predictors of blood 
pressure response, we used mixed-effects models with 
an unstructured covariance matrix for repeat observations 
in the same patient. In substudy 3, we also used mixed 
models for blood pressure response to amiloride versus 
other active treatments or placebo.
Substudy 1: plasma aldosterone, 
renin, and aldosterone-to-renin 
ratio (n=126) 
PATHWAY-2 trial (n=314)
77
Substudy 2: haemodynamic 
analyses (n=226) 
 
Substudy 3: amiloride study
(n=146) 
61
48
40
13
22
8
Overlap of patients participating 
in the PATHWAY-2 mechanisms 
substudies
Aldosterone
Haemodynamics
Amiloride
Figure 2: Participant numbers and measurements in the PATHWAY-2 
mechanisms substudies
Substudies Main trial 
(n=314)
Aldosterone 
(n=126)
Haemodynamics 
(n=226)
Amiloride 
(n=146)
Age, years 60·3 (9·6) 61·1 (9·5) 59·6 (10·1) 61·2 (9·6)
Men 86 (70%) 159 (70%) 109 (75%) 217 (69%)
Women 40 (30%) 67 (30%) 37 (25%) 97 (31%)
Bodyweight, kg 94·1 (17·6) 94·9 (19·0) 96·9 (20·3) 93·9 (18·3)
Systolic blood pressure, mm Hg 159·0 (14·3) 156·7 (14·2) 158·0 (14·0) 157·4 (14·3)
Diastolic blood pressure, mm Hg 92·4 (11·4) 89·9 (11·7) 91·0 (11·3) 90·3 (11·5)
Heart rate, beats per min 77·0 (12·3) 77·5 (11·9) 77·8 (11·1) 77·3 (12·2)
24 h urine Na+, mmol 151·6 (74·7) 148·5 (73·5) 153·0 (73·5) 138·1 (71·7)
24 h urine K+, mmol 79·0 (27·4) 72·5 (28·3) 77·4 (29·6) 70·8 (29·7)
Plasma Na+, mmol/L 139·2 (3·2) 139·7 (3·1) 140·1 (2·8) 139·6 (3·0)
Plasma K+, mmol/L 4·07 (0·44) 4·08 (0·46) 4·02 (0·41) 4·08 (0·44)
eGFR, mL/min/1·73m² 97·4 (26·6) 93·1 (26·6) 97·6 (25·5) 91·6 (26·8)
Diabetes 12 (10%) 39 (17%) 22 (15%) 43 (14%)
Renin, mU/L 33 (14·0–77·0) 33 (13·5–71·5) 34 (14·0–92·0) 34 (14·0–95·0)
Aldosterone, pmol/L 262 (179–352) 247 (178–343) 270 (187–353) 262 (179–352)
Data are mean (SD), n (%), or median (IQR). eGFR=estimated glomerular filtration rate.
Table: Baseline characteristics of patients in the PATHWAY-2 trial and the PATHWAY-2 mechanisms 
substudies
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In the mixed models, patients were defined as random 
effects, with no structure imposed on the within-subject 
covariance matrix, and all other covariates were regarded 
as fixed. Analyses were done with SAS, version 9.3 
(Cary, NC, USA). Data checking for compliance with 
protocol were done by the Robertson Centre for 
Biostatistics, University of Glasgow (UK). The PATHWAY-2 
trial is registered with EudraCT, number 2008–007149–30, 
and ClinicalTrials.gov, number NCT02369081.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or the writing 
of the report. The investigators and all authors had sole 
discretion in the data analysis, interpretation, writing of 
the report, and the decision to submit for publication. 
The corresponding author had full access to all of the data 
and the final responsibility to submit for publication.
Results
Between May 15, 2009, and July 8, 2014, we screened 
436 patients for the PATHWAY-2 study. 335 were randomly 
assigned to treatment groups, of whom 21 had no follow-up 
for any drug and were excluded from the intention-to-treat 
analysis, which comprised 314 patients. Of these, 
126 patients had baseline measurements of aldosterone 
and ARR, 226 participated in the haemo dynamic analyses 
with impedance cardiography, and 146 participated in the 
amiloride runout phase of the study (figure 2).
The baseline characteristics of the patients in the 
three substudies and the overall trial population were 
similar (table). The mean baseline clinic blood pressure 
in the overall trial population was 157·4/90·3 mm Hg 
(SD 14·3/11·5); baseline electrolytes and estimated 
glomerular filtration rate (eGFR) were normal; and 24-h 
urinary sodium concentrations were about 150 mmol 
(equivalent to a salt intake of 9 g per day).
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Figure 3: Correlations of plasma aldosterone, renin, and ARR, with blood pressure response to spironolactone averaged (mean) across the 6-week and 
12-week visits of each treatment cycle
(A) Relation between baseline plasma renin, aldosterone, and the ARR and the home systolic blood pressure response to spironolactone. (B) Best-fit relation between 
plasma aldosterone and renin concentrations at baseline. Regression equations for change in systolic blood pressure (y): y=(–25·20)+6·86 × (log10renin), r²=0·116 
(proportion of variance accounted for by the model); y=8·92–9·85 × (log10aldosterone), r²=0·034; and y=(–8·87)–6·87 × (log10ARR), r²=0·138. Regression equation for 
aldosterone vs renin: log10aldosterone=2·60–0·279 × (log10renin) + 0·081 × (log10renin)², r²=0·043. ARR=aldosterone-to-renin ratio.
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In substudy 1, the blood pressure-lowering response 
to spironolactone was predicted, in order of significance, 
by baseline ARR (r²=0·13, p<0·0001), by plasma renin 
(r²=0·11, p=0·00024; greatest in patients whose plasma 
renin was suppressed), and weakly by plasma 
aldosterone alone (r²=0·025, p=0·052; figure 3A). No 
evident asso ciations were identified between baseline 
plasma renin, aldosterone, or the ARR and the blood 
pressure response to placebo, doxazosin, or bisoprolol 
(appendix).
Aldosterone and renin concentrations were not 
linearly correlated (r²=0·0026, slope –0·019 [SE 0·032]). 
The best fit was quadratic (r²=0·043, p=0·060; figure 3B). 
42 patients were in the lowest tertile of plasma renin 
concentration (renin <19 mU/L), of which 31 had a 
plasma aldosterone concentration greater than the mean 
for all 126 patients (250 pmol/L). Thus, a prevalence of 
31 (25% [95% CI 17–33]) of 126 patients was inferred for 
inappropriately high aldosterone concen trations (ie, 
higher than average aldosterone in association with low 
plasma renin). Of the 42 patients in the highest tertile 
(renin >55 mU/L), 20 had a plasma aldosterone 
concentration greater than the mean. A post-hoc analysis 
by sex showed a significant quadratic association 
between aldosterone and renin concen trations in men 
(r²=0·090, p=0·016), but not in women (r²=0·005, 
p=0·87; appendix). Further exploration of the prevalence 
of primary aldosteronism in this cohort was prompted 
by the paucity of datapoints in the left lower quadrants of 
the graphs (figure 3B; appendix), together with the 
superiority of spirono lactone versus conven tional 
antihypertensive drugs in achieving target blood 
pressure in the main study and the prediction of blood 
pressure response by ARR. Lower and upper estimates 
for prevalence were reached using two published 
criteria. 13 (10% [95% CI 6–17]) of 126 patients, all 
of whom were receiving maximum tolerated doses of 
ACE inhibitor or ARB, had an ARR greater than 
60·94 pmol/mU, the recently validated threshold for 
post-captopril suppression.12 A less conservative estimate 
was obtained using the SUSPPUP index of sodium 
and potassium clearance: 48 (38%, 95% CI 33–43) of 126 
patients had a value greater than 5·3 (mmol L–¹)–¹.13 
Similar to ARR, SUSPPUP predicted home systolic 
blood pressure response to spironolactone, but not to 
the other trial drugs (appendix).
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Figure 4: Change in haemodynamic parameters from baseline after 12 weeks treatment with spironolactone, doxazosin, bisoprolol, and placebo
Stroke index, cardiac index, vascular resistance index, and thoracic fluid index were measured at baseline and the end of each double-blind treatment cycle. Least 
squares means adjusted for gender, height, weight, smoking history, baseline systolic blood pressure, and the baseline measurement of the outcome, from a mixed 
model allowing for correlations between repeat measurements in each patient. Coloured bars show least squares mean values and black bars show 95% CIs.
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In substudy 2, the changes in cardiac output, systemic 
vascular resistance, and thoracic fluid volume from 
baseline to the end of the 12-week treatment cycle with 
each treatment were assessed (figure 4). Spironolactone 
significantly reduced thoracic fluid index by about 
6·8% (95% CI 4·0 to 8·8), with a change of –1·0 1/kΩ/m² 
(95% CI –1·3 to –0·6; p<0·0001). Thoracic fluid index 
was significantly increased by 0·57 1/kΩ/m² with 
doxazosin compared with placebo (95% CI 0·26 to 0·89; 
p=0·00035; figure 4; appendix). Changes in thoracic 
fluid were associated with similar changes in 
bodyweight (appendix). Bisoprolol reduced cardiac 
index by 0·17 L/min/m² (0·07–0·28; p=0·0018) and 
increased stroke volume index by 6·5 mL per heart beat 
per m² (4·9–8·2; p<0·0001), reflecting a reduction in 
heart rate. Vascular resistance index showed a small 
but significant reduction with all treatments, including 
placebo, with no apparent differences between 
treatments (p=0·066). Baseline haemo dynamic charac-
teristics did not predict the blood pressure response to 
treatment (appendix).
In the 144 patients who entered the amiloride runout 
phase (substudy 3), clinic blood pressure after 6 weeks 
was similar to the patients’ previous measurements on 
spironolactone, and much lower than those on either 
placebo or the other two active treatments (p<0·0001; 
figure 5). The reductions in clinic systolic blood 
pressure from baseline to 6 weeks were 20·4 mm Hg 
(95% CI 18·3–22·5) with 10 mg amiloride and 
18·3 mm Hg (16·2–20·5) with 25 mg spironolactone 
(appendix). The superiority of amiloride over other 
drugs and placebo was similar to that reported for 
spironolactone for all patients in the main trial. During 
the runout phase, no forced up-titration was done. In 
47 patients whose blood pressure remained uncontrolled 
after 6 weeks of treatment with amiloride 10 mg daily 
and so were given 20 mg for the second 6 weeks, a 
similar dose-response as for spironolactone 25–50 mg 
was seen (appendix). At both doses, a correlation existed 
between the systolic blood pressure-lowering effect of 
amiloride and spironolactone (r²=0·64, p<0·0001; 
figure 6). No signifi cant change in plasma sodium or 
eGFR occurred with either amiloride or spironolactone 
treatment, but plasma potassium concentrations 
increased from 4·02 mmol/L (95% CI 3·95–4·08) with 
placebo to 4·50 (4·44–4·57) with amiloride and to 4·35 
(4·28–4·42) with spironolactone (both p<0·0001; 
appendix). No serious adverse events were recorded 
with either spironolactone or amiloride. Other adverse 
events were not systematically recorded during the 
open-label phase of PATHWAY-2. Adverse events 
recorded during double-blind treatment with amiloride 
are published elsewhere.7
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Figure 5: Effect of placebo, amiloride, spironolactone, doxazosin, and 
bisoprolol on clinic blood pressure after 6 weeks of treatment
Both amiloride and spironolactone reduced systolic and diastolic blood pressure 
(unadjusted means) versus placebo (p<0·0001) and versus both doxazosin or 
bisoprolol (p<0·0001). The horizontal line at 140 mm Hg shows target clinic 
systolic blood pressure. Coloured bars show mean values and black bars show 
95% CIs. 
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Discussion
The results of our three PATHWAY-2 mechanistic 
substudies show that the blood pressure response to 
spironolactone in resistant hypertension is predicted by 
ARR and by plasma renin alone, that the superior 
reduction of blood pressure achieved with spironolactone 
is associated with elimination of thoracic volume excess 
rather than vasodilatation, and that amiloride is similarly 
effective as spironolactone in reducing blood pressure in 
patients with resistant hypertension. We also showed 
that 31 (25%) of 126 patients have an inappropriately high 
plasma aldosterone concentration—ie, that is greater 
than the mean for all patients in the substudy despite a 
plasma renin concentration in the lowest tertile.
The PATHWAY-2 study was designed to test the 
hypothesis that resistant hypertension is a salt-retaining 
state, and that the best treatment is additional diuretic.3 
The hypothesis was supported by the primary and 
secondary outcomes of the study. The aldosterone 
antagonist spironolactone was substantially more 
effective at reducing blood pressure than the licensed 
antihypertensive drugs bisoprolol and doxazosin, and the 
reduction in blood pressure with spironolactone was 
predicted by baseline plasma renin concentrations.3 
The study was not designed to establish whether 
the mechanism of diuresis (or choice of diuretic) was 
crucial to the outcome. However, results from the other 
studies from the PATHWAY programme suggested that 
the reduction of blood pressure after addition of 
spironolactone was greater than would have been 
achieved by increasing the dose of thiazide. In particular, 
the findings from PATHWAY-3 showed that doubling the 
dose of hydrochlorothiazide from 25 to 50 mg reduced 
blood pressure by 4 mm Hg less than the combination of 
hydrochlorothiazide 25 mg with amiloride 10 mg in 
patients with hypertension.7
The rationale for the extra measurements or inter-
vention that we report here was to link the pathophysiology 
of resistant hypertension with response to treatment. 
This link became of particular interest when the primary 
outcome showed spironolactone to be substantially 
superior to the alternatives. Although this outcome was 
scarcely a complete surprise, we had not expected 
superiority to be exhibited across almost the entire 
distribution of plasma renin, with the crossover design 
permitting demonstration that only ten (3%) of 
326 patients in PATHWAY-2 had a plasma renin concen-
tration that predicted better blood pressure response to 
α blockade or β blockade than to spirono lactone. It seems 
reasonable now to conclude that resistant hypertension, 
as previously suspected,14 is predominantly a salt-retaining 
state, often caused by primary or secondary aldosteronism.
One of the best measures of sodium balance is plasma 
renin, as shown by the dose-related, several-times 
increases in plasma renin caused by each of the diuretic 
treatments in PATHWAY-3.7 Definition of normal ranges 
for plasma renin is difficult in patients receiving multiple 
antihypertensive drugs—in particular the A+C+D classes 
required for a diagnosis of resistant hypertension, all of 
which increase concentrations of plasma renin.15 However, 
the median plasma renin value of 34 mU/L in PATHWAY-2 
was only three times greater than the median value 
(11 mU/L) in the 605 patients with untreated hyper-
tension in PATHWAY-1, who had similar blood pressure 
values on no treatment.16 Because we can compare the 
same patient’s response to each of a diuretic drug 
(spironolactone; efficacy inversely correlated to renin) and 
RAS-blocking drug (bisoprolol; positively correlated), we 
can establish the point between the bottom and top of the 
renin distribution at which the diuretic is predicted by the 
plasma renin concentration to be less effective than 
the RAS blocker (appendix). In the patients with resistant 
hypertension in PATHWAY-2, this point lies at the 
extreme right of the renin distribution, with all but 3% of 
patients predicted to respond better to diuretic than RAS 
blocker. This finding is in striking contrast to the effects 
seen in the previously untreated patients of PATHWAY-1, 
in whom a crossover comparison of hydro chlorothiazide 
25 mg and losartan 100 mg was done, and the diuretic 
efficacy is predicted by plasma renin concentration to 
exceed that of the RAS blocker in fewer than half the 
patients.16 Notably, the relatively low median plasma renin 
in PATHWAY-2 is not due to impaired renal clearance 
because the eGFR was normal. Nor was it due to excessive 
dietary sodium intake as the 24 h urinary sodium was 
typical of that seen in western Europe.17
Aldosterone secretion is normally suppressed when 
renin is low, unless there is autonomous aldosterone 
production—eg, from an aldosterone-producing adenoma. 
This aldosterone suppression is apparent during acute salt 
loading, in cross-sectional studies of dietary sodium intake, 
in some of the rare monogenic causes of hypertension, 
and in patients whose low-renin hypertension is due to 
derivatives of naturally occurring mineralocorticoids.18–20 
Unsuppressed plasma aldosterone values raise suspicion 
that they are the driver of salt retention. The paucity of 
patients with low plasma aldosterone and low plasma 
renin in our study is consistent with aldosterone having a 
primary role in many patients with resistant hyper-
tension.14,21 However, none of the patients, even one whose 
hypertension was cured by removal of a 7 mm aldosterone-
producing adenoma,22 exhibited the triad of spontaneous 
hypo kalaemia, completely suppressed renin, and plasma 
aldosterone of more than 550 pmol/L that is currently 
required for diagnosis of primary aldosteronism if a 
suppression test (the alternative method of diagnosis) is to 
be avoided.21
The absence of this triad could be anticipated from the 
eligibility criteria for PATHWAY-2. Yet, despite our 
exclusion of patients with known or suspected secondary 
hypertension, even the more conservative of our 
estimates for primary aldosteronism frequency (10%) 
exceeds the prevalence of 99 (5·9%) of 1672 unselected 
patients with hypertension who were recruited from 
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primary care (like most patients in PATHWAY-2), and is 
similar to the 126 (11·2%) of 1125 newly diagnosed 
patients referred to specialist clinics.23,24 Our estimate was 
enabled by the recent prospective comparison of confir-
matory tests for primary aldo steronism, showing that a 
post-captopril ARR greater than 60·94 pmol/mU is 
equivalent to a positive saline suppression test, because 
all patients at entry to PATHWAY-2 were already treated 
with maximum-tolerated doses of RAS blocker. At most, 
nine patients might have been excluded from 
PATHWAY-2 if entry had (implausibly) required two ARR 
estimations in all screened patients and follow-up 
confirmatory tests when ARR was higher than 
60·94 pmol/mU.
However, the criteria for suspecting and diagnosing 
primary aldosteronism are likely to miss many of the zona 
glomerulosa subtype of aldosterone-producing adenomas. 
Their responsiveness to angiotensin and frequent gain-of-
function mutations in an L-type calcium channel25,26 imply 
that their aldosterone secretion might be reduced by RAS 
or calcium blockers sufficiently to decrease to less than 
guideline thresholds, but insufficiently to prevent 
increasingly severe and high-risk hypertension. Zona 
glomerulosa-like aldosterone-producing adenomas, unlike 
the classical Conn’s adenoma, are more common in men 
than in women, are often small, and are more likely to 
present as resistant hypertension than a CT finding.25–28 
Our post-hoc finding of sex difference in the aldosterone–
renin association is therefore notable in this context. The 
same is true of unilateral or bilateral hyper plasia, the 
pathological basis on which is increasingly recognised as 
clusters of aldosterone synthase-rich zona glomerulosa 
cells. These clusters have a several-times higher expression 
of adrenocorticotropic hormone receptors than adjacent 
zona glomerulosa, and many clusters have the same 
somatic mutations as are found in zona glomerulosa-like 
adenomas.29
We have therefore reported an analysis independent of 
ARR, which points to a substantially higher upper 
estimate for prevalence of primary aldosteronism in 
patients with resistant hypertension than the 10% 
estimated by ARR. Acute changes in aldosterone 
concentrations can result in dramatic changes in urine 
sodium-to-potassium ratio.30 At a steady state, these are 
less apparent, but they contribute to an index based on 
the SUSPPUP ratio that has only slightly lower accuracy 
than ARR itself in detecting patients with proven primary 
aldosteronism.13 The correlation of blood pressure 
response to spironolactone but not to the other drugs in 
PATHWAY-2 offers some independent support for the 
sodium-to-potassium or SUSPPUP ratio as a diagnostic 
threshold. The 48 (38%) of 126 PATHWAY-2 substudy 
patients who had a ratio greater than the published 
threshold13 of 5·3 (mmol L–¹)–¹ is similar to the proportion 
of unselected patients with hypertension who have an 
apparently normal ARR but develop acute hyper-
aldosteronism on stress (eg, treadmill test) or ultra-low 
dose (30 ng) of adrenocorticotropic hormone.31 In 
one study,32 the SUSPPUP threshold of 5·3 (mmol L–¹)–¹ 
had lower accuracy; however, some variation is 
unsurprising because ARR itself has no single, 
universally agreed threshold.21
What practical role, then, do we now envisage for the 
assessments and interventions reported here? The non-
invasive haemo dynamic measurements were previously 
proposed as a device for selecting the best treatment in 
resistant hypertension.10 However, we did not find the 
measure ments to be useful for prediction, perhaps 
because only one drug was the best in the large majority 
of patients. Of greater practical value might be our finding 
that amiloride seems similarly effective to spironolactone 
in the treatment of resistant hypertension. The efficacy 
and tolerability of amiloride when used in adequate 
doses are supported by our randomised comparison of 
amiloride 10–20 mg with hydro chlorothiazide 25–50 mg 
in PATHWAY-3.7 Although spironolactone was well 
tolerated over 12 weeks, gynaecomastia is a concern with 
longer-term treatment. Retrospective reports that its 
anti-androgen activity is associated with lower incidence 
of carcinoma of the prostate might persuade some 
patients to tolerate the gynaecomastia.33,34 Amiloride could 
now be considered an alternative for patients in whom 
spironolactone is not tolerated.
As for the increased awareness of primary aldosteronism 
as a potentially preventable or curable cause of resistant 
hypertension, possible investigations and treatments in 
selected centres and patients will probably vary greatly, as 
will what can be more widely recommended on the basis 
of available clinical and health economic evidence. 
Prospective evaluation of sodium-to-potassium ratios 
might allow their use as an initial screening filter. 
Management of primary aldosteronism is rapidly 
changing as less invasive modalities become available for 
diagnosis and treatment of functional adenomas.35
Our study has some limitations. By design, only some of 
the patients in PATHWAY-2 participated in the various 
substudies. However, baseline characteristics were similar 
between the cohorts. Prospective power was calculated for 
the primary outcome in PATHWAY-2, but not for the 
individual substudies, which were intended to allow 
prespecified, secondary mechanistic analyses that might 
help to explain the results of the main study. In our favour, 
the size of the study proved much larger than necessary to 
detect the primary outcome, having been powered to 
detect a difference of only 3 mm Hg between spirono-
lactone and other drugs, at an α of 0·003;3,6 indeed, 
post-hoc analysis of the first cycle of treatment showed the 
superiority of spironolactone in just 80 patients.3 Urine 
aldosterone measurements might have helped to confirm 
a high prevalence of primary aldosteronism. Finally, the 
similarity and correlation of the amiloride responses 
with those previously measured on spironolactone add 
qualified support for use of open-label treatment to 
simplify and encourage complex rotation studies,6 but do 
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not guarantee that the two potassium-sparing diuretics 
are interchangeable. The finding that only the spirono-
lactone response correlated with SUSPPUP might point 
to spironolactone as the more effective drug when 
aldosterone is the cause of sodium retention, and 
amiloride when the cause is clearly downstream.
We conclude that the mineralocorticoid receptor 
antagonist spironolactone is an effective treatment of 
resistant hypertension because resistant hypertension is 
commonly a salt-retaining condition probably due to 
inappropriate aldosterone secretion. Amiloride seems to 
be an effective, well tolerated alternative to spironolactone. 
Finally, our findings should encourage debate about 
whether thresholds for diagnosis of primary aldo-
steronism should be reconsidered in patients presenting 
with resistant hypertension, and about the possibility of 
earlier diagnosis of primary aldosteronism to prevent 
development of resistant hypertension.
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